Wedbush is not changing the firm’s positive bias on Viridian Therapeutics (VRDN) after its competitor Acelyrin (SLRN) hosted an investor event to disclose lonigutamab Phase 2 data and plans for Phase 3 studies. While Wedbush wonders about the feasibility of the lonigutamab timeline, it sees Viridian as holding a more competitive program in thyroid eye disease with subcutaneously administered VRDN-003, which is in Phase 3 studies. The company remains on track to report Phase 3 VRDN-003 results in the second half of 2026, the analyst tells investors in a research note. Wedbush continues to like the current entry point, saying Viridian’s cash offers a runway into the second half of 2027, or well past a potential veligrotug commercial launch and completion of VRDN-003 Phase 3 studies. It keeps an Outperform rating on the shares with a $48 price target.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRDN:
- Micron downgraded, Block upgraded: Wall Street’s top analyst calls
- Viridian Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
- Top 3 Trending Stocks, According to Analysts – 12/18/2024
- Viridian Therapeutics price target raised to $47 from $44 at RBC Capital
- Honeywell still exploring alternatives, Capri weighs Versace sale: Morning Buzz
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
